BRPI0717509A2 - sistema de liberação controlada para aplicação nasal de neurotransmissores - Google Patents

sistema de liberação controlada para aplicação nasal de neurotransmissores

Info

Publication number: BRPI0717509A2
Authority: BR; Brazil
Prior art keywords: nasal; neurotransmitter; application; controlled release; release system
Prior art date: 2006-10-04

Application number

BRPI0717509A

Other languages

English (en)

Inventor

Mattern Claudia

Original Assignee

M&P Patent Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-10-04

Filing date

2007-09-27

Publication date

2016-05-17

2007-09-27 Application filed by M&P Patent Ag filed Critical M&P Patent Ag

2016-05-17 Publication of BRPI0717509A2 publication Critical patent/BRPI0717509A2/pt

2019-11-26 Publication of BRPI0717509B1 publication Critical patent/BRPI0717509B1/pt

2021-05-25 Publication of BRPI0717509B8 publication Critical patent/BRPI0717509B8/pt

Links

239000002858 neurotransmitter agent Substances 0.000 title abstract 3
238000013270 controlled release Methods 0.000 title 1
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 abstract 2
210000004556 brain Anatomy 0.000 abstract 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 2
ORNBQBCIOKFOEO-YQUGOWONSA-N Pregnenolone Natural products O=C(C)[C@@H]1[C@@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC3)C[C@@H](O)CC4)CC2)CC1 ORNBQBCIOKFOEO-YQUGOWONSA-N 0.000 abstract 1
239000004480 active ingredient Substances 0.000 abstract 1
229960003638 dopamine Drugs 0.000 abstract 1
238000009472 formulation Methods 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
ORNBQBCIOKFOEO-QGVNFLHTSA-N pregnenolone Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 ORNBQBCIOKFOEO-QGVNFLHTSA-N 0.000 abstract 1
229960000249 pregnenolone Drugs 0.000 abstract 1
229960003387 progesterone Drugs 0.000 abstract 1
239000000186 progesterone Substances 0.000 abstract 1
229940076279 serotonin Drugs 0.000 abstract 1
210000002966 serum Anatomy 0.000 abstract 1
230000002459 sustained effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Emergency Medicine (AREA)
Addiction (AREA)
Psychiatry (AREA)
Otolaryngology (AREA)
Dispersion Chemistry (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Plant Substances (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BRPI0717509A 2006-10-04 2007-09-27 sistema de liberação controlada para aplicação nasal de neurotransmissores BRPI0717509B8 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US82810906P	2006-10-04	2006-10-04
PCT/EP2007/008409 WO2008040488A1 (en)	2006-10-04	2007-09-27	Controlled release delivery system for nasal application of neurotransmitters

Publications (3)

Publication Number	Publication Date
BRPI0717509A2 true BRPI0717509A2 (pt)	2016-05-17
BRPI0717509B1 BRPI0717509B1 (pt)	2019-11-26
BRPI0717509B8 BRPI0717509B8 (pt)	2021-05-25

Family

ID=38799348

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0717509A BRPI0717509B8 (pt)	2006-10-04	2007-09-27	sistema de liberação controlada para aplicação nasal de neurotransmissores

Country Status (19)

Country	Link
US (4)	US20090227550A1 (pt)
EP (1)	EP2068825B1 (pt)
JP (1)	JP5248510B2 (pt)
KR (1)	KR101307133B1 (pt)
CN (1)	CN101600417B (pt)
AT (1)	ATE496617T1 (pt)
AU (1)	AU2007304471B2 (pt)
BR (1)	BRPI0717509B8 (pt)
CA (1)	CA2664427C (pt)
DE (1)	DE602007012276D1 (pt)
DK (1)	DK2068825T3 (pt)
ES (1)	ES2358619T3 (pt)
MX (1)	MX2009003654A (pt)
NO (1)	NO339802B1 (pt)
PL (1)	PL2068825T3 (pt)
PT (1)	PT2068825E (pt)
RU (1)	RU2480208C2 (pt)
WO (1)	WO2008040488A1 (pt)
ZA (1)	ZA200902902B (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8784869B2 (en)	2003-11-11	2014-07-22	Mattern Pharma Ag	Controlled release delivery system for nasal applications and methods of treatment
ATE319426T1 (de)	2003-11-11	2006-03-15	Mattern Udo	Nasenformulierung mit kontrollierter freisetzung von sexualhormonen
US20060140820A1 (en)	2004-12-28	2006-06-29	Udo Mattern	Use of a container of an inorganic additive containing plastic material
CA2664427C (en)	2006-10-04	2012-06-05	M & P Patent Aktiengesellschaft	Controlled release delivery system for nasal application of neurotransmitters
US9757388B2 (en)	2011-05-13	2017-09-12	Acerus Pharmaceuticals Srl	Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
CN103687587A (zh)	2011-05-13	2014-03-26	特利默生物医药有限公司	鼻内较低剂量强度睾酮凝胶制剂及其用于治疗性快感缺失病或性欲减退疾患的应用
US20130045958A1 (en)	2011-05-13	2013-02-21	Trimel Pharmaceuticals Corporation	Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
AR086400A1 (es)	2011-05-13	2013-12-11	Trimel Pharmaceuticals Corp	Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo
BR112013029332A2 (pt) *	2011-05-15	2021-06-01	Trimel Biopharma Srl	formulações de gel bioadesivas de testosterona intranasais e uso das mesmas para tratar hipogonadismo de indivíduo do sexo masculino
US9301920B2 (en)	2012-06-18	2016-04-05	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US8633178B2 (en)	2011-11-23	2014-01-21	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US20150196640A1 (en)	2012-06-18	2015-07-16	Therapeuticsmd, Inc.	Progesterone formulations having a desirable pk profile
US10806740B2 (en)	2012-06-18	2020-10-20	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US10806697B2 (en)	2012-12-21	2020-10-20	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en)	2012-06-18	2013-12-19	Therapeuticsmd, Inc.	Transdermal hormone replacement therapies
DE102012015248A1 (de) *	2012-08-05	2014-02-06	Naum Goldstein	Verfahren zur Einbringung biologisch aktiver Substanzen ins Gehirn
US10568891B2 (en)	2012-12-21	2020-02-25	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en)	2012-12-21	2015-11-10	Therapeuticsmd, Inc.	Soluble estradiol capsule for vaginal insertion
US10537581B2 (en)	2012-12-21	2020-01-21	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en)	2012-12-21	2022-03-08	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en)	2012-12-21	2022-02-15	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en)	2012-12-21	2019-11-12	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US11744838B2 (en)	2013-03-15	2023-09-05	Acerus Biopharma Inc.	Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
EP3145489A1 (en)	2014-05-22	2017-03-29	TherapeuticsMD, Inc.	Natural combination hormone replacement formulations and therapies
JP6597611B2 (ja) *	2014-07-25	2019-10-30	日本電気株式会社	画像処理装置、監視システム、画像処理方法、及びプログラム
RU2016141135A (ru)	2014-07-29	2018-08-28	Терапьютиксмд, Инк.	Трансдермальный крем
US10328087B2 (en)	2015-07-23	2019-06-25	Therapeuticsmd, Inc.	Formulations for solubilizing hormones
WO2017173044A1 (en)	2016-04-01	2017-10-05	Therapeuticsmd Inc.	Steroid hormone compositions in medium chain oils
WO2017173071A1 (en)	2016-04-01	2017-10-05	Therapeuticsmd, Inc.	Steroid hormone pharmaceutical composition
US11903951B2 (en) *	2016-06-03	2024-02-20	M et P Pharma AG	Nasal pharmaceutical compositions with a porous excipient
KR20190109452A (ko) *	2017-01-20	2019-09-25	엠 이티 피 파마 아게	대기 오염 물질에의 노출 위험을 감소시키기 위한 비강 약학적 조성물
CA3087840A1 (en)	2018-01-11	2019-07-18	M et P Pharma AG	Treatment of demyelinating diseases
WO2019148140A2 (en) *	2018-01-26	2019-08-01	Wu Joseph C	Implantable biomaterials that enhance stem cell survival and function
IL277801B2 (en)	2018-04-09	2025-06-01	Katana Pharmaceuticals Inc	Oxytocin compositions and methods of use
CA3097090A1 (en) *	2018-04-17	2019-10-24	M et P Pharma AG	Compositions and methods for intranasal delivery of pregnenolone
CA3198930A1 (en) *	2020-11-19	2022-05-27	Acousia Therapeutics Gmbh	Non-aqueous gel composition

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE943792C (de)	1949-02-18	1956-06-01	Organon Nv	Verfahren zur Herstellung von injizierbaren Hormonpraeparaten
GB1032874A (en)	1964-02-13	1966-06-15	Du Pont	Stabilized polyoxymethylenes
US3769424A (en)	1970-10-01	1973-10-30	Merck & Co Inc	Composition and method of treating dopamine deficiency in brain tissue
US4123417A (en)	1974-10-10	1978-10-31	Mobil Oil Corporation	Low density polyethylene toughened with ethylene/propylene copolymer
NL7506407A (nl)	1975-05-30	1976-12-02	Akzo Nv	Werkwijze ter bereiding van een oraal werkzaam far- maceutisch preparaat.
NL7510104A (nl)	1975-08-27	1977-03-01	Akzo Nv	Werkwijze ter bereiding van een oraal werkzaam farmaceutisch preparaat.
DE2548413A1 (de)	1975-10-27	1977-04-28	Schering Ag	Depotpraeparate in oeliger ungesaettigter loesung zur intramuskulaeren injektion
US4315925A (en)	1980-05-30	1982-02-16	University Of Kentucky Research Foundation	Method of administering natural female sex hormones
DE3151912A1 (de)	1981-12-23	1983-06-30	Schering Ag, 1000 Berlin Und 4619 Bergkamen	Neue ergolin-aminoderivate, verfahren zu ihrer herstellung und deren verwendung als arzneimittel
US4546882A (en)	1983-02-07	1985-10-15	American Can Company	Package having oil-containing product
US4581255A (en) *	1983-08-30	1986-04-08	Abitibi-Price Corporation	Method of making simulated ceramic tile
JPS60136283U (ja)	1984-02-22	1985-09-10	株式会社シマノ	キヤリバ−ブレ−キ
ZA852884B (en) *	1984-04-25	1986-11-26	Lilly Co Eli	Sustained release intranasal formulation and method of use thereof
US4581225A (en)	1984-04-25	1986-04-08	Eli Lilly And Company	Sustained release intranasal formulation and method of use thereof
US4812448A (en)	1984-10-22	1989-03-14	Knepper Paul A	Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension
US4752425A (en)	1986-09-18	1988-06-21	Liposome Technology, Inc.	High-encapsulation liposome processing method
US4786678A (en)	1986-12-29	1988-11-22	Mobil Oil Corporation	Method of producing films from polyethylene resin, an additive and a second polymeric resin
US5049387A (en)	1987-03-09	1991-09-17	Alza Corporation	Inducing skin tolerance to a sensitizing drug
US5690954A (en)	1987-05-22	1997-11-25	Danbiosyst Uk Limited	Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material
JPS646716A (en)	1987-06-27	1989-01-11	Suzuki Motor Co	Displacement measuring apparatus
JP2543708B2 (ja)	1987-07-13	1996-10-16	旭化成工業株式会社	難溶性薬物を封入したエマルジョン製剤の製造方法
JPH01160916A (ja) *	1987-12-18	1989-06-23	Tanabe Seiyaku Co Ltd	ドーパミン経鼻投与製剤
NL8801670A (nl)	1988-07-01	1990-02-01	Walter Adrianus Josephus Johan	Farmaceutisch preparaat.
GB2237510B (en)	1989-11-04	1993-09-15	Danbiosyst Uk	Small particle drug compositions for nasal administration
US5397771A (en)	1990-05-10	1995-03-14	Bechgaard International Research And Development A/S	Pharmaceutical preparation
US5624960A (en) *	1991-01-23	1997-04-29	Isis Pharma Gmbh	Orally administrable drugs for the treatment of central dopamine deficiency conditions
US5500261A (en)	1991-05-24	1996-03-19	Kao Corporation	Resin composition and a container
US5221698A (en)	1991-06-27	1993-06-22	The Regents Of The University Of Michigan	Bioactive composition
US5756071A (en)	1992-06-03	1998-05-26	Arrowdean Limited	Method for nasally administering aerosols of therapeutic agents to enhance penetration of the blood brain barrier
DE4218291A1 (de)	1992-06-03	1993-12-09	Mattern Et Partner Pharmazeuti	Dosierspray für pernasale Applikation
SE9301171D0 (sv)	1993-04-07	1993-04-07	Ab Astra	Pharmaceutical composition containing lipophilic drugs
CA2182577C (en)	1994-02-04	2002-08-20	Anders Carlsson	Lipophilic carrier preparations
GB9405304D0 (en)	1994-03-16	1994-04-27	Scherer Ltd R P	Delivery systems for hydrophobic drugs
US5635203A (en)	1994-09-29	1997-06-03	Alza Corporation	Transdermal device having decreased delamination
WO1996011022A1 (en)	1994-10-05	1996-04-18	Hisamitsu Pharmaceutical Co., Inc.	DRUG COMPOUNDING INGREDIENTS COMPRISING N-SUBSTITUTED-o-TOLUIDINE DERIVATIVE AND PERCUTANEOUSLY ABSORBABLE PREPARATION
US5747058A (en)	1995-06-07	1998-05-05	Southern Biosystems, Inc.	High viscosity liquid controlled delivery system
GB9608719D0 (en)	1996-04-26	1996-07-03	Scherer Ltd R P	Pharmaceutical compositions
GB9707934D0 (en)	1997-04-18	1997-06-04	Danbiosyst Uk	Improved delivery of drugs to mucosal surfaces
US6624200B2 (en)	1998-08-25	2003-09-23	Columbia Laboratories, Inc.	Bioadhesive progressive hydration tablets
US5877216A (en)	1997-10-28	1999-03-02	Vivus, Incorporated	Treatment of female sexual dysfunction
US5897894A (en)	1997-12-29	1999-04-27	General Mills, Inc.	Microwave popcorn with coarse salt crystals and method of preparation
CA2331640A1 (en) *	1998-05-07	1999-11-11	Elan Corporation Plc	Solvent/cosolvent free microemulsion and emulsion preconcentrate drug delivery systems
FR2779438B1 (fr)	1998-06-03	2004-12-24	Jean Marc Aiache	Gel stable, son procede de preparation, et compositions pharmaceutiques le comprenant
GB9823246D0 (en)	1998-10-24	1998-12-16	Danbiosyst Uk	A nasal drug delivery composition
US6838091B2 (en) *	1998-12-18	2005-01-04	Abbott Laboratories	Formulations comprising lipid-regulating agents
US6319905B1 (en) *	1998-12-29	2001-11-20	Cell Genesys, Inc.	Method of controlling L-Dopa production and of treating dopamine deficiency
GB9828861D0 (en)	1998-12-31	1999-02-17	Danbiosyst Uk	Compositions
US6761903B2 (en)	1999-06-30	2004-07-13	Lipocine, Inc.	Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6248363B1 (en)	1999-11-23	2001-06-19	Lipocine, Inc.	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6294192B1 (en)	1999-02-26	2001-09-25	Lipocine, Inc.	Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
HU229455B1 (en)	1999-04-01	2013-12-30	Merck Sharp & Dohme	Formulation comprising testosteron undecanoate and castor oil
US6287588B1 (en)	1999-04-29	2001-09-11	Macromed, Inc.	Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
US6583129B1 (en)	1999-06-11	2003-06-24	Watson Pharmaceuticals, Inc.	Administration of non-oral androgenic steroids to women
AU7984200A (en)	1999-09-21	2001-04-24	Skyepharma Canada Inc.	Surface modified particulate compositions of biologically active substances
US6720001B2 (en)	1999-10-18	2004-04-13	Lipocine, Inc.	Emulsion compositions for polyfunctional active ingredients
US6231662B1 (en)	1999-10-25	2001-05-15	George K. Atkinson	Surface treatments for titanium dioxide and other industrial pigments
CA2325106A1 (en)	1999-12-06	2001-06-06	Stanley L. Gore	Compositions and methods for intranasal delivery of active agents to the brain
US8980290B2 (en)	2000-08-03	2015-03-17	Antares Pharma Ipl Ag	Transdermal compositions for anticholinergic agents
US20030139384A1 (en)	2000-08-30	2003-07-24	Dudley Robert E.	Method for treating erectile dysfunction and increasing libido in men
US20020072509A1 (en)	2000-10-11	2002-06-13	Stein Donald Gerald	Methods for the treatment of a traumatic central nervous system injury
TW586946B (en)	2000-12-22	2004-05-11	Novartis Ag	Process to improve stability
US20020114933A1 (en)	2000-12-28	2002-08-22	Gould Richard J.	Grease masking packaging materials and methods thereof
US6730330B2 (en)	2001-02-14	2004-05-04	Gw Pharma Limited	Pharmaceutical formulations
WO2002069906A2 (en)	2001-03-06	2002-09-12	Cellegy Pharmaceuticals, Inc.	Compounds and methods for the treatment of urogenital disorders
US20040028613A1 (en) *	2001-06-25	2004-02-12	Nastech Pharmaceutical Company Inc	Dopamine agonist formulations for enhanced central nervous system delivery
US6833478B2 (en) *	2001-07-13	2004-12-21	Sri International	N,N-dinitramide salts as solubilizing agents for biologically active agents
EP1423276A1 (en)	2001-08-30	2004-06-02	Toray Plastics (America), Inc.	Polyolefin oil resistant film using porous particles
US6815506B2 (en)	2001-10-15	2004-11-09	Jsr Corporation	Oil-resistant thermoplastic elastomer composition and moldings using the same
DE60320940D1 (de)	2002-02-01	2008-06-26	Pfizer Prod Inc	Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
US6855332B2 (en)	2002-07-03	2005-02-15	Lyfjathroun Hf.	Absorption promoting agent
US7029657B2 (en)	2002-08-02	2006-04-18	Balance Pharmaceuticals, Inc.	Nasal spray steroid formulation and method
US6958142B2 (en)	2002-08-02	2005-10-25	Balance Pharmaceuticals, Inc.	Nasal spray formulation and method
US20040259852A1 (en)	2003-06-18	2004-12-23	White Hillary D.	Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
ATE319426T1 (de) *	2003-11-11	2006-03-15	Mattern Udo	Nasenformulierung mit kontrollierter freisetzung von sexualhormonen
US8784869B2 (en)	2003-11-11	2014-07-22	Mattern Pharma Ag	Controlled release delivery system for nasal applications and methods of treatment
WO2005065185A2 (en)	2003-12-24	2005-07-21	Collegium Pharmaceuticals, Inc.	Temperature-stable formulations, and methods of development thereof
US20060140820A1 (en)	2004-12-28	2006-06-29	Udo Mattern	Use of a container of an inorganic additive containing plastic material
US20070134332A1 (en) *	2005-11-21	2007-06-14	Medivas, Llc	Polymer particles for delivery of macromolecules and methods of use
CA2664427C (en)	2006-10-04	2012-06-05	M & P Patent Aktiengesellschaft	Controlled release delivery system for nasal application of neurotransmitters

2007
- 2007-09-27 CA CA2664427A patent/CA2664427C/en active Active
- 2007-09-27 PL PL07818492T patent/PL2068825T3/pl unknown
- 2007-09-27 AT AT07818492T patent/ATE496617T1/de active
- 2007-09-27 KR KR1020097009279A patent/KR101307133B1/ko not_active Expired - Fee Related
- 2007-09-27 CN CN2007800448143A patent/CN101600417B/zh not_active Expired - Fee Related
- 2007-09-27 MX MX2009003654A patent/MX2009003654A/es active IP Right Grant
- 2007-09-27 PT PT07818492T patent/PT2068825E/pt unknown
- 2007-09-27 AU AU2007304471A patent/AU2007304471B2/en not_active Ceased
- 2007-09-27 EP EP07818492A patent/EP2068825B1/en active Active
- 2007-09-27 RU RU2009116609/15A patent/RU2480208C2/ru active
- 2007-09-27 WO PCT/EP2007/008409 patent/WO2008040488A1/en not_active Ceased
- 2007-09-27 BR BRPI0717509A patent/BRPI0717509B8/pt not_active IP Right Cessation
- 2007-09-27 DK DK07818492.6T patent/DK2068825T3/da active
- 2007-09-27 ZA ZA200902902A patent/ZA200902902B/xx unknown
- 2007-09-27 ES ES07818492T patent/ES2358619T3/es active Active
- 2007-09-27 DE DE602007012276T patent/DE602007012276D1/de active Active
- 2007-09-27 JP JP2009530783A patent/JP5248510B2/ja not_active Expired - Fee Related
2009
- 2009-04-06 US US12/418,917 patent/US20090227550A1/en not_active Abandoned
- 2009-04-28 NO NO20091695A patent/NO339802B1/no unknown
2011
- 2011-07-30 US US13/194,926 patent/US9186320B2/en active Active
2015
- 2015-10-13 US US14/881,332 patent/US9801834B2/en active Active
2017
- 2017-09-26 US US15/716,337 patent/US20180200203A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DK2068825T3 (da)	2011-05-16
AU2007304471B2 (en)	2012-09-06
CA2664427A1 (en)	2008-04-10
US20160089347A1 (en)	2016-03-31
JP5248510B2 (ja)	2013-07-31
PL2068825T3 (pl)	2011-06-30
RU2480208C2 (ru)	2013-04-27
AU2007304471A1 (en)	2008-04-10
PT2068825E (pt)	2011-02-11
CA2664427C (en)	2012-06-05
CN101600417A (zh)	2009-12-09
HK1137658A1 (en)	2010-08-06
WO2008040488A1 (en)	2008-04-10
US20120009249A1 (en)	2012-01-12
US9186320B2 (en)	2015-11-17
JP2010505778A (ja)	2010-02-25
US20180200203A1 (en)	2018-07-19
RU2009116609A (ru)	2010-11-10
ZA200902902B (en)	2010-07-28
NO339802B1 (no)	2017-02-06
ATE496617T1 (de)	2011-02-15
KR101307133B1 (ko)	2013-09-12
CN101600417B (zh)	2012-05-30
NO20091695L (no)	2009-06-23
US9801834B2 (en)	2017-10-31
ES2358619T3 (es)	2011-05-12
EP2068825B1 (en)	2011-01-26
BRPI0717509B1 (pt)	2019-11-26
MX2009003654A (es)	2009-04-22
EP2068825A1 (en)	2009-06-17
US20090227550A1 (en)	2009-09-10
KR20090098958A (ko)	2009-09-18
DE602007012276D1 (de)	2011-03-10
BRPI0717509B8 (pt)	2021-05-25

Legal Events

Date	Code	Title	Description
2018-01-16	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-24	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-07-02	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-07-16	B06T	Formal requirements before examination [chapter 6.20 patent gazette]
2019-11-05	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2019-11-26	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/11/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/11/2019, OBSERVADAS AS CONDICOES LEGAIS
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/09/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF
2024-07-23	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE A 17A ANUIDADE.
2024-11-12	B24J	Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)	Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2794 DE 23-07-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
BRPI0717509A2 (pt)	2016-05-17	sistema de liberação controlada para aplicação nasal de neurotransmissores
CR20110110A (es)	2011-04-28	Composicion farmaceutica
BR112013012587A2 (pt)	2016-09-06	composição farmacêutica para administração nasal
CL2016001809A1 (es)	2017-01-27	Derivados 11-hidroxilo de acidos biliares y conjugados de aminoacidos de los mismos como moduladores del receptor de farnesoid x (divisional sol. n° 3344-15).
BRPI0416370A (pt)	2007-05-22	sistema de distribuição de liberação controlada para aplicações nasais
CR11740A (es)	2011-01-21	Composiciones que comprenden fármacos levemente básicos y formas de dosificación de liberación controlada
BR112015023658A2 (pt)	2017-07-18	formulação de vitamina d de liberação modificada, estabilizada e método de administração desta
GT200500045A (es)	2005-10-31	Solidos supersaturados estabilizados de drogas lipofilicas
MX2010009043A (es)	2010-10-25	Composicion farmaceutica para farmacos poco solubles.
WO2012174158A3 (en)	2014-05-01	Administration of benzodiazepine
BR112012024432A2 (pt)	2016-05-31	composição farmacêutica de dissolução rápida
PH12013502325A1 (en)	2014-02-10	Drug delivery system
CL2013002700A1 (es)	2014-07-11	Cápsula suave ingerible que contiene inositol y excipientes, o inositol, excipientes y al menos un principio activo adicional, tal como ácido fólico, polifenoles de cocoa, genisteína, l-arginina, vitamina e, selenio, n-acetilcisteína y melatonina; útil para el tratamiento del ovario poliquístico, resistencia a la insulina y otros
MX2015008021A (es)	2016-03-04	Composiciones y metodos para administracion transdermica de hormonas y otros agentes medicos.
CL2011002807A1 (es)	2012-06-15	Mezcla farmaceutica comprimible que comprende cristales de un farmaco con tamaño de particulas inferior a 40 um y un adyuvante de la disolucion; procedimiento para preparar un vehiculo de administracion para un farmaco que incluye moler una premezcla de cristales de farmaco y un adyuvante de la disolucion.
MX2014010537A (es)	2015-03-09	Moduladores de receptor x del higado (lxr) para el tratamiento de enfermedades, trastornos y condiciones dermicas.
EA201400737A1 (ru)	2014-12-30	Система доставки на основе множества пеллет с немедленным высвобождением активного вещества
BR112018014123A2 (pt)	2018-12-11	formulação farmacêutica aquosa estável.
MD4591B1 (ro)	2018-09-30	Dispersie solidă a unui modulator selectiv al receptorului de progesteron
BR112014009242A8 (pt)	2017-06-20	nanossuspensão farmacêutica
WO2009076413A3 (en)	2009-08-06	Methods, devices and compositions for controlled drug delivery to injured myocardium
BR112015010243A2 (pt)	2017-07-11	dispersão sólida, composição para administração oral, composição farmacêutica, e, método para preparar uma dispersão sólida
MY166972A (en)	2018-07-27	Transdermal delivery system containing galantamine or salts thereof
DOP2013000115A (es)	2014-07-31	Formulación de un complejo que comprende clorhidrato de lercanidipina y valsartán y método para la preparación de la misma
BR112018012616A2 (pt)	2018-12-04	formulação galênica que compreende um fármaco tópico